#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


Text=Time‐dependent neuronal changes associated with craving in opioid dependence: an fMRI study Abstract Relapse after initially successful treatment is a significant problem facing the treatment of opioid dependence.
1-1	0-14	Time‐dependent	_
1-2	15-23	neuronal	_
1-3	24-31	changes	_
1-4	32-42	associated	_
1-5	43-47	with	_
1-6	48-55	craving	_
1-7	56-58	in	_
1-8	59-65	opioid	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse
1-9	66-76	dependence	_
1-10	77-78	:	_
1-11	79-81	an	_
1-12	82-86	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
1-13	87-92	study	_
1-14	93-101	Abstract	_
1-15	102-109	Relapse	_
1-16	110-115	after	_
1-17	116-125	initially	_
1-18	126-136	successful	_
1-19	137-146	treatment	_
1-20	147-149	is	_
1-21	150-151	a	_
1-22	152-163	significant	_
1-23	164-171	problem	_
1-24	172-178	facing	_
1-25	179-182	the	_
1-26	183-192	treatment	_
1-27	193-195	of	_
1-28	196-202	opioid	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse
1-29	203-213	dependence	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse
1-30	214-215	.	_

Text=Evidence suggests craving elicited by re‐exposure to drug cues may precipitate relapse.
2-1	216-224	Evidence	_
2-2	225-233	suggests	_
2-3	234-241	craving	_
2-4	242-250	elicited	_
2-5	251-253	by	_
2-6	254-265	re‐exposure	_
2-7	266-268	to	_
2-8	269-273	drug	_
2-9	274-278	cues	_
2-10	279-282	may	_
2-11	283-294	precipitate	_
2-12	295-302	relapse	_
2-13	303-304	.	_

Text=Attempts to identify neural biomarkers of cue‐elicited craving have yielded inconsistent findings.
3-1	305-313	Attempts	_
3-2	314-316	to	_
3-3	317-325	identify	_
3-4	326-332	neural	_
3-5	333-343	biomarkers	_
3-6	344-346	of	_
3-7	347-359	cue‐elicited	_
3-8	360-367	craving	_
3-9	368-372	have	_
3-10	373-380	yielded	_
3-11	381-393	inconsistent	_
3-12	394-402	findings	_
3-13	403-404	.	_

Text=We aimed to apply a novel continuous functional magnetic resonance imaging technique to follow the minute‐to‐minute evolution of brain responses, which correlate with the waxing and waning of craving.
4-1	405-407	We	_
4-2	408-413	aimed	_
4-3	414-416	to	_
4-4	417-422	apply	_
4-5	423-424	a	_
4-6	425-430	novel	_
4-7	431-441	continuous	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
4-8	442-452	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
4-9	453-461	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
4-10	462-471	resonance	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
4-11	472-479	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
4-12	480-489	technique	_
4-13	490-492	to	_
4-14	493-499	follow	_
4-15	500-503	the	_
4-16	504-520	minute‐to‐minute	_
4-17	521-530	evolution	_
4-18	531-533	of	_
4-19	534-539	brain	_
4-20	540-549	responses	_
4-21	550-551	,	_
4-22	552-557	which	_
4-23	558-567	correlate	_
4-24	568-572	with	_
4-25	573-576	the	_
4-26	577-583	waxing	_
4-27	584-587	and	_
4-28	588-594	waning	_
4-29	595-597	of	_
4-30	598-605	craving	_
4-31	606-607	.	_

Text=Newly detoxified male opioid‐dependent patients and healthy control participants attended two separate, counterbalanced, functional magnetic resonance imaging scanning sessions during which they viewed a 10‐minute video (drug cue or neutral cue) followed by 5 minutes of fixation.
5-1	608-613	Newly	_
5-2	614-624	detoxified	_
5-3	625-629	male	_
5-4	630-646	opioid‐dependent	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse
5-5	647-655	patients	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse
5-6	656-659	and	_
5-7	660-667	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
5-8	668-675	control	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
5-9	676-688	participants	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
5-10	689-697	attended	_
5-11	698-701	two	_
5-12	702-710	separate	_
5-13	711-712	,	_
5-14	713-728	counterbalanced	_
5-15	729-730	,	_
5-16	731-741	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
5-17	742-750	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
5-18	751-760	resonance	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
5-19	761-768	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
5-20	769-777	scanning	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
5-21	778-786	sessions	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
5-22	787-793	during	_
5-23	794-799	which	_
5-24	800-804	they	_
5-25	805-811	viewed	_
5-26	812-813	a	_
5-27	814-823	10‐minute	_
5-28	824-829	video	_
5-29	830-831	(	_
5-30	832-836	drug	_
5-31	837-840	cue	_
5-32	841-843	or	_
5-33	844-851	neutral	_
5-34	852-855	cue	_
5-35	856-857	)	_
5-36	858-866	followed	_
5-37	867-869	by	_
5-38	870-871	5	_
5-39	872-879	minutes	_
5-40	880-882	of	_
5-41	883-891	fixation	_
5-42	892-893	.	_

Text=Participants rated the intensity of their craving throughout each session.
6-1	894-906	Participants	_
6-2	907-912	rated	_
6-3	913-916	the	_
6-4	917-926	intensity	_
6-5	927-929	of	_
6-6	930-935	their	_
6-7	936-943	craving	_
6-8	944-954	throughout	_
6-9	955-959	each	_
6-10	960-967	session	_
6-11	968-969	.	_

Text=We hypothesized that subcortical/ventral prefrontal cortex (PFC) regions and dorsal PFC regions would show different associations with craving reflecting their putative roles in appetitive processing versus cognitive control.
7-1	970-972	We	_
7-2	973-985	hypothesized	_
7-3	986-990	that	_
7-4	991-1010	subcortical/ventral	_
7-5	1011-1021	prefrontal	_
7-6	1022-1028	cortex	_
7-7	1029-1030	(	_
7-8	1031-1034	PFC	_
7-9	1035-1036	)	_
7-10	1037-1044	regions	_
7-11	1045-1048	and	_
7-12	1049-1055	dorsal	_
7-13	1056-1059	PFC	_
7-14	1060-1067	regions	_
7-15	1068-1073	would	_
7-16	1074-1078	show	_
7-17	1079-1088	different	_
7-18	1089-1101	associations	_
7-19	1102-1106	with	_
7-20	1107-1114	craving	_
7-21	1115-1125	reflecting	_
7-22	1126-1131	their	_
7-23	1132-1140	putative	_
7-24	1141-1146	roles	_
7-25	1147-1149	in	_
7-26	1150-1160	appetitive	_
7-27	1161-1171	processing	_
7-28	1172-1178	versus	_
7-29	1179-1188	cognitive	_
7-30	1189-1196	control	_
7-31	1197-1198	.	_

Text=Compared with controls, drug cue (minus neutral cue) video recruited the left amygdala and was temporally correlated with craving.
8-1	1199-1207	Compared	_
8-2	1208-1212	with	_
8-3	1213-1221	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
8-4	1222-1223	,	_
8-5	1224-1228	drug	_
8-6	1229-1232	cue	_
8-7	1233-1234	(	_
8-8	1235-1240	minus	_
8-9	1241-1248	neutral	_
8-10	1249-1252	cue	_
8-11	1253-1254	)	_
8-12	1255-1260	video	_
8-13	1261-1270	recruited	_
8-14	1271-1274	the	_
8-15	1275-1279	left	_
8-16	1280-1288	amygdala	_
8-17	1289-1292	and	_
8-18	1293-1296	was	_
8-19	1297-1307	temporally	_
8-20	1308-1318	correlated	_
8-21	1319-1323	with	_
8-22	1324-1331	craving	_
8-23	1332-1333	.	_

Text=In contrast, dorsal anterior cingulate blood‐oxygen‐level‐dependent signal time course was higher than controls only during a period after cue exposure when craving levels were declining.
9-1	1334-1336	In	_
9-2	1337-1345	contrast	_
9-3	1346-1347	,	_
9-4	1348-1354	dorsal	_
9-5	1355-1363	anterior	_
9-6	1364-1373	cingulate	_
9-7	1374-1402	blood‐oxygen‐level‐dependent	_
9-8	1403-1409	signal	_
9-9	1410-1414	time	_
9-10	1415-1421	course	_
9-11	1422-1425	was	_
9-12	1426-1432	higher	_
9-13	1433-1437	than	_
9-14	1438-1446	controls	_
9-15	1447-1451	only	_
9-16	1452-1458	during	_
9-17	1459-1460	a	_
9-18	1461-1467	period	_
9-19	1468-1473	after	_
9-20	1474-1477	cue	_
9-21	1478-1486	exposure	_
9-22	1487-1491	when	_
9-23	1492-1499	craving	_
9-24	1500-1506	levels	_
9-25	1507-1511	were	_
9-26	1512-1521	declining	_
9-27	1522-1523	.	_

Text=Against expectations, neither the ventral striatum nor ventral PFC was significantly recruited by drug cue exposure.
10-1	1524-1531	Against	_
10-2	1532-1544	expectations	_
10-3	1545-1546	,	_
10-4	1547-1554	neither	_
10-5	1555-1558	the	_
10-6	1559-1566	ventral	_
10-7	1567-1575	striatum	_
10-8	1576-1579	nor	_
10-9	1580-1587	ventral	_
10-10	1588-1591	PFC	_
10-11	1592-1595	was	_
10-12	1596-1609	significantly	_
10-13	1610-1619	recruited	_
10-14	1620-1622	by	_
10-15	1623-1627	drug	_
10-16	1628-1631	cue	_
10-17	1632-1640	exposure	_
10-18	1641-1642	.	_

Text=Findings suggest that the amygdala has a central role in craving, whereas the dorsal anterior cingulate may control craving in treatment‐seeking patients.
11-1	1643-1651	Findings	_
11-2	1652-1659	suggest	_
11-3	1660-1664	that	_
11-4	1665-1668	the	_
11-5	1669-1677	amygdala	_
11-6	1678-1681	has	_
11-7	1682-1683	a	_
11-8	1684-1691	central	_
11-9	1692-1696	role	_
11-10	1697-1699	in	_
11-11	1700-1707	craving	_
11-12	1708-1709	,	_
11-13	1710-1717	whereas	_
11-14	1718-1721	the	_
11-15	1722-1728	dorsal	_
11-16	1729-1737	anterior	_
11-17	1738-1747	cingulate	_
11-18	1748-1751	may	_
11-19	1752-1759	control	_
11-20	1760-1767	craving	_
11-21	1768-1770	in	_
11-22	1771-1788	treatment‐seeking	_
11-23	1789-1797	patients	_
11-24	1798-1799	.	_

Text=Time course analysis yielded new insights into the neural substrates of craving that could objectively validate development of psychological and pharmacological approaches to sustained abstinence.
12-1	1800-1804	Time	_
12-2	1805-1811	course	_
12-3	1812-1820	analysis	_
12-4	1821-1828	yielded	_
12-5	1829-1832	new	_
12-6	1833-1841	insights	_
12-7	1842-1846	into	_
12-8	1847-1850	the	_
12-9	1851-1857	neural	_
12-10	1858-1868	substrates	_
12-11	1869-1871	of	_
12-12	1872-1879	craving	_
12-13	1880-1884	that	_
12-14	1885-1890	could	_
12-15	1891-1902	objectively	_
12-16	1903-1911	validate	_
12-17	1912-1923	development	_
12-18	1924-1926	of	_
12-19	1927-1940	psychological	_
12-20	1941-1944	and	_
12-21	1945-1960	pharmacological	_
12-22	1961-1971	approaches	_
12-23	1972-1974	to	_
12-24	1975-1984	sustained	_
12-25	1985-1995	abstinence	_
12-26	1996-1997	.	_

Text=Methods and Materials Participants Opioid‐dependent individuals (n = 18) This study was approved by the NHS Research Ethics Committee.
13-1	1998-2005	Methods	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
13-2	2006-2009	and	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
13-3	2010-2019	Materials	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
13-4	2020-2032	Participants	_
13-5	2033-2049	Opioid‐dependent	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
13-6	2050-2061	individuals	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
13-7	2062-2063	(	_
13-8	2064-2065	n	_
13-9	2066-2067	=	_
13-10	2068-2070	18	_
13-11	2071-2072	)	_
13-12	2073-2077	This	_
13-13	2078-2083	study	_
13-14	2084-2087	was	_
13-15	2088-2096	approved	_
13-16	2097-2099	by	_
13-17	2100-2103	the	_
13-18	2104-2107	NHS	_
13-19	2108-2116	Research	_
13-20	2117-2123	Ethics	_
13-21	2124-2133	Committee	_
13-22	2134-2135	.	_

Text=Participants with OD were recruited from a residential detoxification unit within Greater Manchester (see Table 1 for demographic information).
14-1	2136-2148	Participants	_
14-2	2149-2153	with	_
14-3	2154-2156	OD	http://maven.renci.org/NeuroBridge/neurobridge#Thing
14-4	2157-2161	were	_
14-5	2162-2171	recruited	_
14-6	2172-2176	from	_
14-7	2177-2178	a	_
14-8	2179-2190	residential	_
14-9	2191-2205	detoxification	_
14-10	2206-2210	unit	_
14-11	2211-2217	within	_
14-12	2218-2225	Greater	_
14-13	2226-2236	Manchester	_
14-14	2237-2238	(	_
14-15	2239-2242	see	_
14-16	2243-2248	Table	_
14-17	2249-2250	1	_
14-18	2251-2254	for	_
14-19	2255-2266	demographic	_
14-20	2267-2278	information	_
14-21	2279-2280	)	_
14-22	2281-2282	.	_

Text=Treatment involved a 4‐week residential stay with a 10‐day methadone stabilization and reduction, followed by 10 days of lofexidine treatment, an alpha‐2 adrenergic receptor agonist used to treat opioid withdrawal symptoms.
15-1	2283-2292	Treatment	_
15-2	2293-2301	involved	_
15-3	2302-2303	a	_
15-4	2304-2310	4‐week	_
15-5	2311-2322	residential	_
15-6	2323-2327	stay	_
15-7	2328-2332	with	_
15-8	2333-2334	a	_
15-9	2335-2341	10‐day	_
15-10	2342-2351	methadone	_
15-11	2352-2365	stabilization	_
15-12	2366-2369	and	_
15-13	2370-2379	reduction	_
15-14	2380-2381	,	_
15-15	2382-2390	followed	_
15-16	2391-2393	by	_
15-17	2394-2396	10	_
15-18	2397-2401	days	_
15-19	2402-2404	of	_
15-20	2405-2415	lofexidine	_
15-21	2416-2425	treatment	_
15-22	2426-2427	,	_
15-23	2428-2430	an	_
15-24	2431-2438	alpha‐2	_
15-25	2439-2449	adrenergic	_
15-26	2450-2458	receptor	_
15-27	2459-2466	agonist	_
15-28	2467-2471	used	_
15-29	2472-2474	to	_
15-30	2475-2480	treat	_
15-31	2481-2487	opioid	_
15-32	2488-2498	withdrawal	_
15-33	2499-2507	symptoms	_
15-34	2508-2509	.	_

Text=Participants took part in the study during the last week of their residential stay when they were opioid free (confirmed by urine drug screen).
16-1	2510-2522	Participants	_
16-2	2523-2527	took	_
16-3	2528-2532	part	_
16-4	2533-2535	in	_
16-5	2536-2539	the	_
16-6	2540-2545	study	_
16-7	2546-2552	during	_
16-8	2553-2556	the	_
16-9	2557-2561	last	_
16-10	2562-2566	week	_
16-11	2567-2569	of	_
16-12	2570-2575	their	_
16-13	2576-2587	residential	_
16-14	2588-2592	stay	_
16-15	2593-2597	when	_
16-16	2598-2602	they	_
16-17	2603-2607	were	_
16-18	2608-2614	opioid	_
16-19	2615-2619	free	_
16-20	2620-2621	(	_
16-21	2622-2631	confirmed	_
16-22	2632-2634	by	_
16-23	2635-2640	urine	_
16-24	2641-2645	drug	_
16-25	2646-2652	screen	_
16-26	2653-2654	)	_
16-27	2655-2656	.	_

Text=Lofexidine was extended at low doses for participants still experiencing withdrawal symptoms during this final week, and some ODs were receiving other psychoactive medications as indicated by Supporting Information Table S1.
17-1	2657-2667	Lofexidine	_
17-2	2668-2671	was	_
17-3	2672-2680	extended	_
17-4	2681-2683	at	_
17-5	2684-2687	low	_
17-6	2688-2693	doses	_
17-7	2694-2697	for	_
17-8	2698-2710	participants	_
17-9	2711-2716	still	_
17-10	2717-2729	experiencing	_
17-11	2730-2740	withdrawal	_
17-12	2741-2749	symptoms	_
17-13	2750-2756	during	_
17-14	2757-2761	this	_
17-15	2762-2767	final	_
17-16	2768-2772	week	_
17-17	2773-2774	,	_
17-18	2775-2778	and	_
17-19	2779-2783	some	_
17-20	2784-2787	ODs	http://maven.renci.org/NeuroBridge/neurobridge#BloodSubstanceMeasurement
17-21	2788-2792	were	_
17-22	2793-2802	receiving	_
17-23	2803-2808	other	_
17-24	2809-2821	psychoactive	_
17-25	2822-2833	medications	_
17-26	2834-2836	as	_
17-27	2837-2846	indicated	_
17-28	2847-2849	by	_
17-29	2850-2860	Supporting	_
17-30	2861-2872	Information	_
17-31	2873-2878	Table	_
17-32	2879-2881	S1	_
17-33	2882-2883	.	_

Text=The OD group was recruited according to the following inclusion criteria: male, aged 18–55; current DSM IV heroin dependence (the majority of patients also met criteria for current or past dependence on other substances; Table 1); no history of serious psychiatric, neurological or physical illness; no contraindications for MRI; and IQ of ≥85 [determined using the Wechsler Test of Adult Reading (Holdnack 2001)].
18-1	2884-2887	The	_
18-2	2888-2890	OD	http://maven.renci.org/NeuroBridge/neurobridge#ParallelGroupTrial
18-3	2891-2896	group	http://maven.renci.org/NeuroBridge/neurobridge#ParallelGroupTrial
18-4	2897-2900	was	_
18-5	2901-2910	recruited	_
18-6	2911-2920	according	_
18-7	2921-2923	to	_
18-8	2924-2927	the	_
18-9	2928-2937	following	_
18-10	2938-2947	inclusion	_
18-11	2948-2956	criteria	_
18-12	2957-2958	:	_
18-13	2959-2963	male	_
18-14	2964-2965	,	_
18-15	2966-2970	aged	_
18-16	2971-2976	18–55	_
18-17	2977-2978	;	_
18-18	2979-2986	current	_
18-19	2987-2990	DSM	_
18-20	2991-2993	IV	_
18-21	2994-3000	heroin	_
18-22	3001-3011	dependence	_
18-23	3012-3013	(	_
18-24	3014-3017	the	_
18-25	3018-3026	majority	_
18-26	3027-3029	of	_
18-27	3030-3038	patients	_
18-28	3039-3043	also	_
18-29	3044-3047	met	_
18-30	3048-3056	criteria	_
18-31	3057-3060	for	_
18-32	3061-3068	current	_
18-33	3069-3071	or	_
18-34	3072-3076	past	_
18-35	3077-3087	dependence	_
18-36	3088-3090	on	_
18-37	3091-3096	other	_
18-38	3097-3107	substances	_
18-39	3108-3109	;	_
18-40	3110-3115	Table	_
18-41	3116-3117	1	_
18-42	3118-3119	)	_
18-43	3120-3121	;	_
18-44	3122-3124	no	_
18-45	3125-3132	history	_
18-46	3133-3135	of	_
18-47	3136-3143	serious	_
18-48	3144-3155	psychiatric	_
18-49	3156-3157	,	_
18-50	3158-3170	neurological	_
18-51	3171-3173	or	_
18-52	3174-3182	physical	_
18-53	3183-3190	illness	_
18-54	3191-3192	;	_
18-55	3193-3195	no	_
18-56	3196-3213	contraindications	_
18-57	3214-3217	for	_
18-58	3218-3221	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
18-59	3222-3223	;	_
18-60	3224-3227	and	_
18-61	3228-3230	IQ	_
18-62	3231-3233	of	_
18-63	3234-3237	≥85	_
18-64	3238-3239	[	_
18-65	3240-3250	determined	_
18-66	3251-3256	using	_
18-67	3257-3260	the	_
18-68	3261-3269	Wechsler	http://maven.renci.org/NeuroBridge/neurobridge#NationalAdultReadingTest
18-69	3270-3274	Test	http://maven.renci.org/NeuroBridge/neurobridge#NationalAdultReadingTest
18-70	3275-3277	of	http://maven.renci.org/NeuroBridge/neurobridge#NationalAdultReadingTest
18-71	3278-3283	Adult	http://maven.renci.org/NeuroBridge/neurobridge#NationalAdultReadingTest
18-72	3284-3291	Reading	http://maven.renci.org/NeuroBridge/neurobridge#NationalAdultReadingTest
18-73	3292-3293	(	_
18-74	3294-3302	Holdnack	_
18-75	3303-3307	2001	_
18-76	3308-3309	)	_
18-77	3310-3311	]	_
18-78	3312-3313	.	_

Text=Participants were identified and approached by members of the clinical team on the basis of detailed physical and mental health assessments on admission to the unit.
19-1	3314-3326	Participants	_
19-2	3327-3331	were	_
19-3	3332-3342	identified	_
19-4	3343-3346	and	_
19-5	3347-3357	approached	_
19-6	3358-3360	by	_
19-7	3361-3368	members	_
19-8	3369-3371	of	_
19-9	3372-3375	the	_
19-10	3376-3384	clinical	_
19-11	3385-3389	team	_
19-12	3390-3392	on	_
19-13	3393-3396	the	_
19-14	3397-3402	basis	_
19-15	3403-3405	of	_
19-16	3406-3414	detailed	_
19-17	3415-3423	physical	_
19-18	3424-3427	and	_
19-19	3428-3434	mental	_
19-20	3435-3441	health	_
19-21	3442-3453	assessments	_
19-22	3454-3456	on	_
19-23	3457-3466	admission	_
19-24	3467-3469	to	_
19-25	3470-3473	the	_
19-26	3474-3478	unit	_
19-27	3479-3480	.	_

Text=All participants meeting the inclusion criteria were approached to take part in the study.
20-1	3481-3484	All	_
20-2	3485-3497	participants	_
20-3	3498-3505	meeting	_
20-4	3506-3509	the	_
20-5	3510-3519	inclusion	_
20-6	3520-3528	criteria	_
20-7	3529-3533	were	_
20-8	3534-3544	approached	_
20-9	3545-3547	to	_
20-10	3548-3552	take	_
20-11	3553-3557	part	_
20-12	3558-3560	in	_
20-13	3561-3564	the	_
20-14	3565-3570	study	_
20-15	3571-3572	.	_

Text=A total of 39 patients were enrolled in the craving study; however, 19 were discharged from the unit before any testing could take place (mainly self‐discharge or early discharge due to use of prohibited substances).
21-1	3573-3574	A	_
21-2	3575-3580	total	_
21-3	3581-3583	of	_
21-4	3584-3586	39	_
21-5	3587-3595	patients	_
21-6	3596-3600	were	_
21-7	3601-3609	enrolled	_
21-8	3610-3612	in	_
21-9	3613-3616	the	_
21-10	3617-3624	craving	_
21-11	3625-3630	study	_
21-12	3631-3632	;	_
21-13	3633-3640	however	_
21-14	3641-3642	,	_
21-15	3643-3645	19	_
21-16	3646-3650	were	_
21-17	3651-3661	discharged	_
21-18	3662-3666	from	_
21-19	3667-3670	the	_
21-20	3671-3675	unit	_
21-21	3676-3682	before	_
21-22	3683-3686	any	_
21-23	3687-3694	testing	_
21-24	3695-3700	could	_
21-25	3701-3705	take	_
21-26	3706-3711	place	_
21-27	3712-3713	(	_
21-28	3714-3720	mainly	_
21-29	3721-3735	self‐discharge	_
21-30	3736-3738	or	_
21-31	3739-3744	early	_
21-32	3745-3754	discharge	_
21-33	3755-3758	due	_
21-34	3759-3761	to	_
21-35	3762-3765	use	_
21-36	3766-3768	of	_
21-37	3769-3779	prohibited	_
21-38	3780-3790	substances	_
21-39	3791-3792	)	_
21-40	3793-3794	.	_

Text=Twenty patients were scanned as part of the study, although two were excluded from analysis because of excessive movement (see Preprocessing section for further details), leaving n = 18 who were included in analysis.
22-1	3795-3801	Twenty	_
22-2	3802-3810	patients	_
22-3	3811-3815	were	_
22-4	3816-3823	scanned	_
22-5	3824-3826	as	_
22-6	3827-3831	part	_
22-7	3832-3834	of	_
22-8	3835-3838	the	_
22-9	3839-3844	study	_
22-10	3845-3846	,	_
22-11	3847-3855	although	_
22-12	3856-3859	two	_
22-13	3860-3864	were	_
22-14	3865-3873	excluded	_
22-15	3874-3878	from	_
22-16	3879-3887	analysis	_
22-17	3888-3895	because	_
22-18	3896-3898	of	_
22-19	3899-3908	excessive	_
22-20	3909-3917	movement	_
22-21	3918-3919	(	_
22-22	3920-3923	see	_
22-23	3924-3937	Preprocessing	_
22-24	3938-3945	section	_
22-25	3946-3949	for	_
22-26	3950-3957	further	_
22-27	3958-3965	details	_
22-28	3966-3967	)	_
22-29	3968-3969	,	_
22-30	3970-3977	leaving	_
22-31	3978-3979	n	_
22-32	3980-3981	=	_
22-33	3982-3984	18	_
22-34	3985-3988	who	_
22-35	3989-3993	were	_
22-36	3994-4002	included	_
22-37	4003-4005	in	_
22-38	4006-4014	analysis	_
22-39	4015-4016	.	_

Text=Handedness was assessed with the Edinburgh Handedness Inventory (Oldfield 1971).
23-1	4017-4027	Handedness	_
23-2	4028-4031	was	_
23-3	4032-4040	assessed	_
23-4	4041-4045	with	_
23-5	4046-4049	the	_
23-6	4050-4059	Edinburgh	_
23-7	4060-4070	Handedness	_
23-8	4071-4080	Inventory	_
23-9	4081-4082	(	_
23-10	4083-4091	Oldfield	_
23-11	4092-4096	1971	_
23-12	4097-4098	)	_
23-13	4099-4100	.	_

Text=Healthy controls (n = 20) Healthy controls (HCs) were recruited who were familiar with graphic scenes of drug use because of occupational experience (e.g.
24-1	4101-4108	Healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
24-2	4109-4117	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
24-3	4118-4119	(	_
24-4	4120-4121	n	_
24-5	4122-4123	=	_
24-6	4124-4126	20	_
24-7	4127-4128	)	_
24-8	4129-4136	Healthy	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
24-9	4137-4145	controls	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
24-10	4146-4147	(	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
24-11	4148-4151	HCs	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
24-12	4152-4153	)	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
24-13	4154-4158	were	_
24-14	4159-4168	recruited	_
24-15	4169-4172	who	_
24-16	4173-4177	were	_
24-17	4178-4186	familiar	_
24-18	4187-4191	with	_
24-19	4192-4199	graphic	_
24-20	4200-4206	scenes	_
24-21	4207-4209	of	_
24-22	4210-4214	drug	_
24-23	4215-4218	use	_
24-24	4219-4226	because	_
24-25	4227-4229	of	_
24-26	4230-4242	occupational	_
24-27	4243-4253	experience	_
24-28	4254-4255	(	_
24-29	4256-4259	e.g	_
24-30	4260-4261	.	_

Text=drug treatment workers and other health professionals).
25-1	4262-4266	drug	_
25-2	4267-4276	treatment	_
25-3	4277-4284	workers	_
25-4	4285-4288	and	_
25-5	4289-4294	other	_
25-6	4295-4301	health	_
25-7	4302-4315	professionals	_
25-8	4316-4317	)	_
25-9	4318-4319	.	_

Text=The HC group met the same inclusion criteria outlined previously and additionally had no current or past history of drug dependence or misuse (except nicotine) and had never used heroin in their lifetime.
26-1	4320-4323	The	_
26-2	4324-4326	HC	http://maven.renci.org/NeuroBridge/neurobridge#ParallelGroupTrial
26-3	4327-4332	group	http://maven.renci.org/NeuroBridge/neurobridge#ParallelGroupTrial
26-4	4333-4336	met	_
26-5	4337-4340	the	_
26-6	4341-4345	same	_
26-7	4346-4355	inclusion	_
26-8	4356-4364	criteria	_
26-9	4365-4373	outlined	_
26-10	4374-4384	previously	_
26-11	4385-4388	and	_
26-12	4389-4401	additionally	_
26-13	4402-4405	had	_
26-14	4406-4408	no	_
26-15	4409-4416	current	_
26-16	4417-4419	or	_
26-17	4420-4424	past	_
26-18	4425-4432	history	_
26-19	4433-4435	of	_
26-20	4436-4440	drug	_
26-21	4441-4451	dependence	_
26-22	4452-4454	or	_
26-23	4455-4461	misuse	_
26-24	4462-4463	(	_
26-25	4464-4470	except	_
26-26	4471-4479	nicotine	_
26-27	4480-4481	)	_
26-28	4482-4485	and	_
26-29	4486-4489	had	_
26-30	4490-4495	never	_
26-31	4496-4500	used	_
26-32	4501-4507	heroin	_
26-33	4508-4510	in	_
26-34	4511-4516	their	_
26-35	4517-4525	lifetime	_
26-36	4526-4527	.	_

Text=No healthy volunteers were receiving psychoactive medications.
27-1	4528-4530	No	_
27-2	4531-4538	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
27-3	4539-4549	volunteers	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
27-4	4550-4554	were	_
27-5	4555-4564	receiving	_
27-6	4565-4577	psychoactive	_
27-7	4578-4589	medications	_
27-8	4590-4591	.	_

Text=Participants were screened with the Mini International Neuropsychiatric Interview (Sheehan et al.
28-1	4592-4604	Participants	_
28-2	4605-4609	were	_
28-3	4610-4618	screened	_
28-4	4619-4623	with	_
28-5	4624-4627	the	_
28-6	4628-4632	Mini	_
28-7	4633-4646	International	_
28-8	4647-4663	Neuropsychiatric	_
28-9	4664-4673	Interview	_
28-10	4674-4675	(	_
28-11	4676-4683	Sheehan	_
28-12	4684-4686	et	_
28-13	4687-4689	al	_
28-14	4690-4691	.	_

Text=1998), Wechsler Test of Adult Reading and Edinburgh Handedness Inventory.
29-1	4692-4696	1998	_
29-2	4697-4698	)	_
29-3	4699-4700	,	_
29-4	4701-4709	Wechsler	http://maven.renci.org/NeuroBridge/neurobridge#NationalAdultReadingTest
29-5	4710-4714	Test	http://maven.renci.org/NeuroBridge/neurobridge#NationalAdultReadingTest
29-6	4715-4717	of	http://maven.renci.org/NeuroBridge/neurobridge#NationalAdultReadingTest
29-7	4718-4723	Adult	http://maven.renci.org/NeuroBridge/neurobridge#NationalAdultReadingTest
29-8	4724-4731	Reading	http://maven.renci.org/NeuroBridge/neurobridge#NationalAdultReadingTest
29-9	4732-4735	and	_
29-10	4736-4745	Edinburgh	http://maven.renci.org/NeuroBridge/neurobridge#EdinburghHandednessInventoryQuestionnaire
29-11	4746-4756	Handedness	http://maven.renci.org/NeuroBridge/neurobridge#EdinburghHandednessInventoryQuestionnaire
29-12	4757-4766	Inventory	http://maven.renci.org/NeuroBridge/neurobridge#EdinburghHandednessInventoryQuestionnaire
29-13	4767-4768	.	_

Text=All participants provided written consent and were paid for their participation with vouchers.
30-1	4769-4772	All	_
30-2	4773-4785	participants	_
30-3	4786-4794	provided	_
30-4	4795-4802	written	_
30-5	4803-4810	consent	_
30-6	4811-4814	and	_
30-7	4815-4819	were	_
30-8	4820-4824	paid	_
30-9	4825-4828	for	_
30-10	4829-4834	their	_
30-11	4835-4848	participation	_
30-12	4849-4853	with	_
30-13	4854-4862	vouchers	_
30-14	4863-4864	.	_

Text=Procedures Participants attended two separate, counterbalanced sessions.
31-1	4865-4875	Procedures	_
31-2	4876-4888	Participants	_
31-3	4889-4897	attended	_
31-4	4898-4901	two	_
31-5	4902-4910	separate	_
31-6	4911-4912	,	_
31-7	4913-4928	counterbalanced	_
31-8	4929-4937	sessions	_
31-9	4938-4939	.	_

Text=Patients were scanned in the last week of their residential stay when they were opioid free.
32-1	4940-4948	Patients	_
32-2	4949-4953	were	_
32-3	4954-4961	scanned	_
32-4	4962-4964	in	_
32-5	4965-4968	the	_
32-6	4969-4973	last	_
32-7	4974-4978	week	_
32-8	4979-4981	of	_
32-9	4982-4987	their	_
32-10	4988-4999	residential	_
32-11	5000-5004	stay	_
32-12	5005-5009	when	_
32-13	5010-5014	they	_
32-14	5015-5019	were	_
32-15	5020-5026	opioid	_
32-16	5027-5031	free	_
32-17	5032-5033	.	_

Text=On each occasion, participants underwent fMRI, once whilst viewing a 10‐minute heroin video (drug cue session) and once whilst viewing a 10‐minute video containing scenes matched for visual complexity but lacking emotionally arousing content (neutral session).
33-1	5034-5036	On	_
33-2	5037-5041	each	_
33-3	5042-5050	occasion	_
33-4	5051-5052	,	_
33-5	5053-5065	participants	_
33-6	5066-5075	underwent	_
33-7	5076-5080	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
33-8	5081-5082	,	_
33-9	5083-5087	once	_
33-10	5088-5094	whilst	_
33-11	5095-5102	viewing	_
33-12	5103-5104	a	_
33-13	5105-5114	10‐minute	_
33-14	5115-5121	heroin	_
33-15	5122-5127	video	_
33-16	5128-5129	(	_
33-17	5130-5134	drug	_
33-18	5135-5138	cue	_
33-19	5139-5146	session	_
33-20	5147-5148	)	_
33-21	5149-5152	and	_
33-22	5153-5157	once	_
33-23	5158-5164	whilst	_
33-24	5165-5172	viewing	_
33-25	5173-5174	a	_
33-26	5175-5184	10‐minute	_
33-27	5185-5190	video	_
33-28	5191-5201	containing	_
33-29	5202-5208	scenes	_
33-30	5209-5216	matched	_
33-31	5217-5220	for	_
33-32	5221-5227	visual	_
33-33	5228-5238	complexity	_
33-34	5239-5242	but	_
33-35	5243-5250	lacking	_
33-36	5251-5262	emotionally	_
33-37	5263-5271	arousing	_
33-38	5272-5279	content	_
33-39	5280-5281	(	_
33-40	5282-5289	neutral	_
33-41	5290-5297	session	_
33-42	5298-5299	)	_
33-43	5300-5301	.	_

Text=Videos were preceded and followed by 5 minutes of fixation (Fig.
34-1	5302-5308	Videos	_
34-2	5309-5313	were	_
34-3	5314-5322	preceded	_
34-4	5323-5326	and	_
34-5	5327-5335	followed	_
34-6	5336-5338	by	_
34-7	5339-5340	5	_
34-8	5341-5348	minutes	_
34-9	5349-5351	of	_
34-10	5352-5360	fixation	_
34-11	5361-5362	(	_
34-12	5363-5366	Fig	_
34-13	5367-5368	.	_

Text=1).
35-1	5369-5370	1	_
35-2	5371-5372	)	_
35-3	5373-5374	.	_

Text=Images were presented using e‐prime (Psychology Software Tools, Inc, Sharpsburg, USA) (version 2.0).
36-1	5375-5381	Images	_
36-2	5382-5386	were	_
36-3	5387-5396	presented	_
36-4	5397-5402	using	_
36-5	5403-5410	e‐prime	_
36-6	5411-5412	(	_
36-7	5413-5423	Psychology	_
36-8	5424-5432	Software	_
36-9	5433-5438	Tools	_
36-10	5439-5440	,	_
36-11	5441-5444	Inc	_
36-12	5445-5446	,	_
36-13	5447-5457	Sharpsburg	_
36-14	5458-5459	,	_
36-15	5460-5463	USA	_
36-16	5464-5465	)	_
36-17	5466-5467	(	_
36-18	5468-5475	version	_
36-19	5476-5479	2.0	_
36-20	5480-5481	)	_
36-21	5482-5483	.	_

Text=Measures Participants were presented with Likert‐like subjective rating scales throughout the scanning session.
37-1	5484-5492	Measures	_
37-2	5493-5505	Participants	_
37-3	5506-5510	were	_
37-4	5511-5520	presented	_
37-5	5521-5525	with	_
37-6	5526-5537	Likert‐like	_
37-7	5538-5548	subjective	_
37-8	5549-5555	rating	_
37-9	5556-5562	scales	_
37-10	5563-5573	throughout	_
37-11	5574-5577	the	_
37-12	5578-5586	scanning	_
37-13	5587-5594	session	_
37-14	5595-5596	.	_

Text=Participants were prompted to respond by a screen displaying the following text ‘ do you feel you are … ’, which was presented for 3 seconds before slides stating ‘ Craving? ’, ‘ Withdrawing? ’, ‘ Anxious? ’ or ‘ High? ’, were presented for 4 seconds along with the following scale: 1 (not all), 2 (slightly), 3 (moderately) and 4 (extremely).
38-1	5597-5609	Participants	_
38-2	5610-5614	were	_
38-3	5615-5623	prompted	_
38-4	5624-5626	to	_
38-5	5627-5634	respond	_
38-6	5635-5637	by	_
38-7	5638-5639	a	_
38-8	5640-5646	screen	_
38-9	5647-5657	displaying	_
38-10	5658-5661	the	_
38-11	5662-5671	following	_
38-12	5672-5676	text	_
38-13	5677-5678	‘	_
38-14	5679-5681	do	_
38-15	5682-5685	you	_
38-16	5686-5690	feel	_
38-17	5691-5694	you	_
38-18	5695-5698	are	_
38-19	5699-5700	…	_
38-20	5701-5702	’	_
38-21	5703-5704	,	_
38-22	5705-5710	which	_
38-23	5711-5714	was	_
38-24	5715-5724	presented	_
38-25	5725-5728	for	_
38-26	5729-5730	3	_
38-27	5731-5738	seconds	_
38-28	5739-5745	before	_
38-29	5746-5752	slides	_
38-30	5753-5760	stating	_
38-31	5761-5762	‘	_
38-32	5763-5770	Craving	_
38-33	5771-5772	?	_
38-34	5773-5774	’	_
38-35	5775-5776	,	_
38-36	5777-5778	‘	_
38-37	5779-5790	Withdrawing	_
38-38	5791-5792	?	_
38-39	5793-5794	’	_
38-40	5795-5796	,	_
38-41	5797-5798	‘	_
38-42	5799-5806	Anxious	_
38-43	5807-5808	?	_
38-44	5809-5810	’	_
38-45	5811-5813	or	_
38-46	5814-5815	‘	_
38-47	5816-5820	High	_
38-48	5821-5822	?	_
38-49	5823-5824	’	_
38-50	5825-5826	,	_
38-51	5827-5831	were	_
38-52	5832-5841	presented	_
38-53	5842-5845	for	_
38-54	5846-5847	4	_
38-55	5848-5855	seconds	_
38-56	5856-5861	along	_
38-57	5862-5866	with	_
38-58	5867-5870	the	_
38-59	5871-5880	following	_
38-60	5881-5886	scale	_
38-61	5887-5888	:	_
38-62	5889-5890	1	_
38-63	5891-5892	(	_
38-64	5893-5896	not	_
38-65	5897-5900	all	_
38-66	5901-5902	)	_
38-67	5903-5904	,	_
38-68	5905-5906	2	_
38-69	5907-5908	(	_
38-70	5909-5917	slightly	_
38-71	5918-5919	)	_
38-72	5920-5921	,	_
38-73	5922-5923	3	_
38-74	5924-5925	(	_
38-75	5926-5936	moderately	_
38-76	5937-5938	)	_
38-77	5939-5942	and	_
38-78	5943-5944	4	_
38-79	5945-5946	(	_
38-80	5947-5956	extremely	_
38-81	5957-5958	)	_
38-82	5959-5960	.	_

Text=Participants responded via a button box.
39-1	5961-5973	Participants	_
39-2	5974-5983	responded	_
39-3	5984-5987	via	_
39-4	5988-5989	a	_
39-5	5990-5996	button	_
39-6	5997-6000	box	_
39-7	6001-6002	.	_

Text=The scales were presented at 3‐minute intervals in each session (Fig.
40-1	6003-6006	The	_
40-2	6007-6013	scales	_
40-3	6014-6018	were	_
40-4	6019-6028	presented	_
40-5	6029-6031	at	_
40-6	6032-6040	3‐minute	_
40-7	6041-6050	intervals	_
40-8	6051-6053	in	_
40-9	6054-6058	each	_
40-10	6059-6066	session	_
40-11	6067-6068	(	_
40-12	6069-6072	Fig	_
40-13	6073-6074	.	_

Text=1) Behavioural data Mixed ANOVAs were carried out for each of the four subjective rating scales with time of rating (six levels including a pre‐video baseline rating, three during the video and two post‐video ratings) and session (drug cue, neutral) as within‐subject factors and group (HC, OD) as the between‐subject factor.
41-1	6075-6076	1	_
41-2	6077-6078	)	_
41-3	6079-6090	Behavioural	_
41-4	6091-6095	data	_
41-5	6096-6101	Mixed	_
41-6	6102-6108	ANOVAs	_
41-7	6109-6113	were	_
41-8	6114-6121	carried	_
41-9	6122-6125	out	_
41-10	6126-6129	for	_
41-11	6130-6134	each	_
41-12	6135-6137	of	_
41-13	6138-6141	the	_
41-14	6142-6146	four	_
41-15	6147-6157	subjective	_
41-16	6158-6164	rating	_
41-17	6165-6171	scales	_
41-18	6172-6176	with	_
41-19	6177-6181	time	_
41-20	6182-6184	of	_
41-21	6185-6191	rating	_
41-22	6192-6193	(	_
41-23	6194-6197	six	_
41-24	6198-6204	levels	_
41-25	6205-6214	including	_
41-26	6215-6216	a	_
41-27	6217-6226	pre‐video	_
41-28	6227-6235	baseline	_
41-29	6236-6242	rating	_
41-30	6243-6244	,	_
41-31	6245-6250	three	_
41-32	6251-6257	during	_
41-33	6258-6261	the	_
41-34	6262-6267	video	_
41-35	6268-6271	and	_
41-36	6272-6275	two	_
41-37	6276-6286	post‐video	_
41-38	6287-6294	ratings	_
41-39	6295-6296	)	_
41-40	6297-6300	and	_
41-41	6301-6308	session	_
41-42	6309-6310	(	_
41-43	6311-6315	drug	_
41-44	6316-6319	cue	_
41-45	6320-6321	,	_
41-46	6322-6329	neutral	_
41-47	6330-6331	)	_
41-48	6332-6334	as	_
41-49	6335-6349	within‐subject	_
41-50	6350-6357	factors	_
41-51	6358-6361	and	_
41-52	6362-6367	group	_
41-53	6368-6369	(	_
41-54	6370-6372	HC	_
41-55	6373-6374	,	_
41-56	6375-6377	OD	_
41-57	6378-6379	)	_
41-58	6380-6382	as	_
41-59	6383-6386	the	_
41-60	6387-6402	between‐subject	_
41-61	6403-6409	factor	_
41-62	6410-6411	.	_

Text=Session order was included as a covariate.
42-1	6412-6419	Session	_
42-2	6420-6425	order	_
42-3	6426-6429	was	_
42-4	6430-6438	included	_
42-5	6439-6441	as	_
42-6	6442-6443	a	_
42-7	6444-6453	covariate	_
42-8	6454-6455	.	_

Text=The pre‐video rating taken during the last minute of the baseline period (T0) was used as the pre‐video baseline rating.
43-1	6456-6459	The	_
43-2	6460-6469	pre‐video	_
43-3	6470-6476	rating	_
43-4	6477-6482	taken	_
43-5	6483-6489	during	_
43-6	6490-6493	the	_
43-7	6494-6498	last	_
43-8	6499-6505	minute	_
43-9	6506-6508	of	_
43-10	6509-6512	the	_
43-11	6513-6521	baseline	_
43-12	6522-6528	period	_
43-13	6529-6530	(	_
43-14	6531-6533	T0	_
43-15	6534-6535	)	_
43-16	6536-6539	was	_
43-17	6540-6544	used	_
43-18	6545-6547	as	_
43-19	6548-6551	the	_
43-20	6552-6561	pre‐video	_
43-21	6562-6570	baseline	_
43-22	6571-6577	rating	_
43-23	6578-6579	.	_

Text=A Greenhouse‐Geisser correction was applied when Mauchley's assumption of sphericity was violated.
44-1	6580-6581	A	_
44-2	6582-6600	Greenhouse‐Geisser	_
44-3	6601-6611	correction	_
44-4	6612-6615	was	_
44-5	6616-6623	applied	_
44-6	6624-6628	when	_
44-7	6629-6637	Mauchley	_
44-8	6638-6640	's	_
44-9	6641-6651	assumption	_
44-10	6652-6654	of	_
44-11	6655-6665	sphericity	_
44-12	6666-6669	was	_
44-13	6670-6678	violated	_
44-14	6679-6680	.	_

Text=Ratings from one HC were not included as the participant could not see the rating scales.
45-1	6681-6688	Ratings	_
45-2	6689-6693	from	_
45-3	6694-6697	one	_
45-4	6698-6700	HC	_
45-5	6701-6705	were	_
45-6	6706-6709	not	_
45-7	6710-6718	included	_
45-8	6719-6721	as	_
45-9	6722-6725	the	_
45-10	6726-6737	participant	_
45-11	6738-6743	could	_
45-12	6744-6747	not	_
45-13	6748-6751	see	_
45-14	6752-6755	the	_
45-15	6756-6762	rating	_
45-16	6763-6769	scales	_
45-17	6770-6771	.	_

Text=Scanning and analysis Whole brain T2 * weighted images were acquired on a 3 Tesla Philips Achieva scanner with single shot, multi‐slice echo planar (EPI) pulse sequence.
46-1	6772-6780	Scanning	_
46-2	6781-6784	and	_
46-3	6785-6793	analysis	_
46-4	6794-6799	Whole	_
46-5	6800-6805	brain	_
46-6	6806-6808	T2	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging
46-7	6809-6810	*	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging
46-8	6811-6819	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging
46-9	6820-6826	images	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging
46-10	6827-6831	were	_
46-11	6832-6840	acquired	_
46-12	6841-6843	on	_
46-13	6844-6845	a	_
46-14	6846-6847	3	http://maven.renci.org/NeuroBridge/neurobridge#DateTimeUnit
46-15	6848-6853	Tesla	http://maven.renci.org/NeuroBridge/neurobridge#WideRangeAchievementTest
46-16	6854-6861	Philips	http://maven.renci.org/NeuroBridge/neurobridge#WideRangeAchievementTest
46-17	6862-6869	Achieva	http://maven.renci.org/NeuroBridge/neurobridge#WideRangeAchievementTest
46-18	6870-6877	scanner	http://maven.renci.org/NeuroBridge/neurobridge#WideRangeAchievementTest
46-19	6878-6882	with	_
46-20	6883-6889	single	_
46-21	6890-6894	shot	_
46-22	6895-6896	,	_
46-23	6897-6908	multi‐slice	_
46-24	6909-6913	echo	http://maven.renci.org/NeuroBridge/neurobridge#PulseOximetry
46-25	6914-6920	planar	http://maven.renci.org/NeuroBridge/neurobridge#PulseOximetry
46-26	6921-6922	(	http://maven.renci.org/NeuroBridge/neurobridge#PulseOximetry
46-27	6923-6926	EPI	http://maven.renci.org/NeuroBridge/neurobridge#PulseOximetry
46-28	6927-6928	)	http://maven.renci.org/NeuroBridge/neurobridge#PulseOximetry
46-29	6929-6934	pulse	http://maven.renci.org/NeuroBridge/neurobridge#PulseOximetry
46-30	6935-6943	sequence	http://maven.renci.org/NeuroBridge/neurobridge#PulseOximetry
46-31	6944-6945	.	_

Text=Each volume comprised 34 contiguous axial slices (TR = 2.5 s, TE = 35 ms, 96 × 96 matrix, in‐plane voxel size 3.0 mm × 3.0 mm, slice thickness 3.5 mm).
47-1	6946-6950	Each	_
47-2	6951-6957	volume	_
47-3	6958-6967	comprised	_
47-4	6968-6970	34	_
47-5	6971-6981	contiguous	_
47-6	6982-6987	axial	_
47-7	6988-6994	slices	_
47-8	6995-6996	(	_
47-9	6997-6999	TR	_
47-10	7000-7001	=	_
47-11	7002-7005	2.5	_
47-12	7006-7007	s	_
47-13	7008-7009	,	_
47-14	7010-7012	TE	_
47-15	7013-7014	=	_
47-16	7015-7017	35	_
47-17	7018-7020	ms	_
47-18	7021-7022	,	_
47-19	7023-7025	96	_
47-20	7026-7027	×	_
47-21	7028-7030	96	_
47-22	7031-7037	matrix	_
47-23	7038-7039	,	_
47-24	7040-7048	in‐plane	_
47-25	7049-7054	voxel	_
47-26	7055-7059	size	_
47-27	7060-7063	3.0	_
47-28	7064-7066	mm	_
47-29	7067-7068	×	_
47-30	7069-7072	3.0	_
47-31	7073-7075	mm	_
47-32	7076-7077	,	_
47-33	7078-7083	slice	_
47-34	7084-7093	thickness	_
47-35	7094-7097	3.5	_
47-36	7098-7100	mm	_
47-37	7101-7102	)	_
47-38	7103-7104	.	_

Text=A high‐resolution T1‐weighted structural image was also acquired for each participant for coregistration during preprocessing and to exclude any structural abnormality.
48-1	7105-7106	A	_
48-2	7107-7122	high‐resolution	_
48-3	7123-7134	T1‐weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
48-4	7135-7145	structural	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
48-5	7146-7151	image	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
48-6	7152-7155	was	_
48-7	7156-7160	also	_
48-8	7161-7169	acquired	_
48-9	7170-7173	for	_
48-10	7174-7178	each	_
48-11	7179-7190	participant	_
48-12	7191-7194	for	_
48-13	7195-7209	coregistration	_
48-14	7210-7216	during	_
48-15	7217-7230	preprocessing	_
48-16	7231-7234	and	_
48-17	7235-7237	to	_
48-18	7238-7245	exclude	_
48-19	7246-7249	any	_
48-20	7250-7260	structural	_
48-21	7261-7272	abnormality	_
48-22	7273-7274	.	_

Text=Preprocessing Functional data were analysed using statistical parametric mapping (SPM8; The Wellcome Department of Cognitive Neurology, London, UK) running in MATLAB (Matlab, R2012a; Mathworks, Natick, Massachusetts, U.S.A.).
49-1	7275-7288	Preprocessing	_
49-2	7289-7299	Functional	_
49-3	7300-7304	data	_
49-4	7305-7309	were	_
49-5	7310-7318	analysed	_
49-6	7319-7324	using	_
49-7	7325-7336	statistical	_
49-8	7337-7347	parametric	_
49-9	7348-7355	mapping	_
49-10	7356-7357	(	_
49-11	7358-7362	SPM8	_
49-12	7363-7364	;	_
49-13	7365-7368	The	_
49-14	7369-7377	Wellcome	_
49-15	7378-7388	Department	_
49-16	7389-7391	of	_
49-17	7392-7401	Cognitive	_
49-18	7402-7411	Neurology	_
49-19	7412-7413	,	_
49-20	7414-7420	London	_
49-21	7421-7422	,	_
49-22	7423-7425	UK	_
49-23	7426-7427	)	_
49-24	7428-7435	running	_
49-25	7436-7438	in	_
49-26	7439-7445	MATLAB	_
49-27	7446-7447	(	_
49-28	7448-7454	Matlab	_
49-29	7455-7456	,	_
49-30	7457-7463	R2012a	_
49-31	7464-7465	;	_
49-32	7466-7475	Mathworks	_
49-33	7476-7477	,	_
49-34	7478-7484	Natick	_
49-35	7485-7486	,	_
49-36	7487-7500	Massachusetts	_
49-37	7501-7502	,	_
49-38	7503-7509	U.S.A.	_
49-39	7510-7511	)	_
49-40	7512-7513	.	_

Text=Functional images were realigned and coregistered with the T1 structural image before normalization of the functional images into standard space was carried out using the unified segmentation approach (Ashburner & Friston 2005).
50-1	7514-7524	Functional	_
50-2	7525-7531	images	_
50-3	7532-7536	were	_
50-4	7537-7546	realigned	_
50-5	7547-7550	and	_
50-6	7551-7563	coregistered	_
50-7	7564-7568	with	_
50-8	7569-7572	the	_
50-9	7573-7575	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
50-10	7576-7586	structural	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
50-11	7587-7592	image	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
50-12	7593-7599	before	_
50-13	7600-7613	normalization	_
50-14	7614-7616	of	_
50-15	7617-7620	the	_
50-16	7621-7631	functional	_
50-17	7632-7638	images	_
50-18	7639-7643	into	_
50-19	7644-7652	standard	_
50-20	7653-7658	space	_
50-21	7659-7662	was	_
50-22	7663-7670	carried	_
50-23	7671-7674	out	_
50-24	7675-7680	using	_
50-25	7681-7684	the	_
50-26	7685-7692	unified	_
50-27	7693-7705	segmentation	_
50-28	7706-7714	approach	_
50-29	7715-7716	(	_
50-30	7717-7726	Ashburner	_
50-31	7727-7728	&	_
50-32	7729-7736	Friston	_
50-33	7737-7741	2005	_
50-34	7742-7743	)	_
50-35	7744-7745	.	_

Text=Normalized images were smoothed using an 8‐mm Gaussian kernel.
51-1	7746-7756	Normalized	_
51-2	7757-7763	images	_
51-3	7764-7768	were	_
51-4	7769-7777	smoothed	_
51-5	7778-7783	using	_
51-6	7784-7786	an	_
51-7	7787-7791	8‐mm	_
51-8	7792-7800	Gaussian	_
51-9	7801-7807	kernel	_
51-10	7808-7809	.	_

Text=The smoothed functional images of the participants who moved more than 1 voxel were repaired by an interpolation method using the artefact repair toolbox (http: //cibsr.stanford.edu/tools/ArtRepair/ArtRepair.htm).
52-1	7810-7813	The	_
52-2	7814-7822	smoothed	_
52-3	7823-7833	functional	_
52-4	7834-7840	images	_
52-5	7841-7843	of	_
52-6	7844-7847	the	_
52-7	7848-7860	participants	_
52-8	7861-7864	who	_
52-9	7865-7870	moved	_
52-10	7871-7875	more	_
52-11	7876-7880	than	_
52-12	7881-7882	1	_
52-13	7883-7888	voxel	_
52-14	7889-7893	were	_
52-15	7894-7902	repaired	_
52-16	7903-7905	by	_
52-17	7906-7908	an	_
52-18	7909-7922	interpolation	_
52-19	7923-7929	method	_
52-20	7930-7935	using	_
52-21	7936-7939	the	_
52-22	7940-7948	artefact	_
52-23	7949-7955	repair	_
52-24	7956-7963	toolbox	_
52-25	7964-7965	(	_
52-26	7966-7970	http	_
52-27	7971-7972	:	_
52-28	7973-8023	//cibsr.stanford.edu/tools/ArtRepair/ArtRepair.htm	_
52-29	8024-8025	)	_
52-30	8026-8027	.	_

Text=Two ODs with excessive movement were excluded (> 10 percent volumes needing repairing).
53-1	8028-8031	Two	_
53-2	8032-8035	ODs	_
53-3	8036-8040	with	_
53-4	8041-8050	excessive	_
53-5	8051-8059	movement	_
53-6	8060-8064	were	_
53-7	8065-8073	excluded	_
53-8	8074-8075	(	_
53-9	8076-8077	>	_
53-10	8078-8080	10	_
53-11	8081-8088	percent	_
53-12	8089-8096	volumes	_
53-13	8097-8104	needing	_
53-14	8105-8114	repairing	_
53-15	8115-8116	)	_
53-16	8117-8118	.	_

Text=Eighteen ODs and 20 HCs were entered into subsequent analyses.
54-1	8119-8127	Eighteen	_
54-2	8128-8131	ODs	_
54-3	8132-8135	and	_
54-4	8136-8138	20	_
54-5	8139-8142	HCs	_
54-6	8143-8147	were	_
54-7	8148-8155	entered	_
54-8	8156-8160	into	_
54-9	8161-8171	subsequent	_
54-10	8172-8180	analyses	_
54-11	8181-8182	.	_

Text=First‐level analysis For both the drug cue and the neutral session, data were acquired continuously for 20 minutes (5 minutes before the start of each video to allow participants to acclimatize to the scanner environment, 10 minutes during presentation of the video and an additional 5 minutes after the end of the video) (Fig.
55-1	8183-8194	First‐level	_
55-2	8195-8203	analysis	_
55-3	8204-8207	For	_
55-4	8208-8212	both	_
55-5	8213-8216	the	_
55-6	8217-8221	drug	_
55-7	8222-8225	cue	_
55-8	8226-8229	and	_
55-9	8230-8233	the	_
55-10	8234-8241	neutral	_
55-11	8242-8249	session	_
55-12	8250-8251	,	_
55-13	8252-8256	data	_
55-14	8257-8261	were	_
55-15	8262-8270	acquired	_
55-16	8271-8283	continuously	_
55-17	8284-8287	for	_
55-18	8288-8290	20	_
55-19	8291-8298	minutes	_
55-20	8299-8300	(	_
55-21	8301-8302	5	_
55-22	8303-8310	minutes	_
55-23	8311-8317	before	_
55-24	8318-8321	the	_
55-25	8322-8327	start	_
55-26	8328-8330	of	_
55-27	8331-8335	each	_
55-28	8336-8341	video	_
55-29	8342-8344	to	_
55-30	8345-8350	allow	_
55-31	8351-8363	participants	_
55-32	8364-8366	to	_
55-33	8367-8378	acclimatize	_
55-34	8379-8381	to	_
55-35	8382-8385	the	_
55-36	8386-8393	scanner	_
55-37	8394-8405	environment	_
55-38	8406-8407	,	_
55-39	8408-8410	10	_
55-40	8411-8418	minutes	_
55-41	8419-8425	during	_
55-42	8426-8438	presentation	_
55-43	8439-8441	of	_
55-44	8442-8445	the	_
55-45	8446-8451	video	_
55-46	8452-8455	and	_
55-47	8456-8458	an	_
55-48	8459-8469	additional	_
55-49	8470-8471	5	_
55-50	8472-8479	minutes	_
55-51	8480-8485	after	_
55-52	8486-8489	the	_
55-53	8490-8493	end	_
55-54	8494-8496	of	_
55-55	8497-8500	the	_
55-56	8501-8506	video	_
55-57	8507-8508	)	_
55-58	8509-8510	(	_
55-59	8511-8514	Fig	_
55-60	8515-8516	.	_

Text=1).
56-1	8517-8518	1	_
56-2	8519-8520	)	_
56-3	8521-8522	.	_

Text=The resultant 480 acquired scans were divided into 1‐minute time‐bins (20 time‐bins in total).
57-1	8523-8526	The	_
57-2	8527-8536	resultant	_
57-3	8537-8540	480	_
57-4	8541-8549	acquired	_
57-5	8550-8555	scans	_
57-6	8556-8560	were	_
57-7	8561-8568	divided	_
57-8	8569-8573	into	_
57-9	8574-8582	1‐minute	_
57-10	8583-8592	time‐bins	_
57-11	8593-8594	(	_
57-12	8595-8597	20	_
57-13	8598-8607	time‐bins	_
57-14	8608-8610	in	_
57-15	8611-8616	total	_
57-16	8617-8618	)	_
57-17	8619-8620	.	_

Text=The 5th minute of the pre‐video baseline was treated as the baseline time‐bin T0, with each subsequent time‐bin (T1–15) compared with T0 using regression analysis within a general linear model framework.
58-1	8621-8624	The	_
58-2	8625-8628	5th	_
58-3	8629-8635	minute	_
58-4	8636-8638	of	_
58-5	8639-8642	the	_
58-6	8643-8652	pre‐video	_
58-7	8653-8661	baseline	_
58-8	8662-8665	was	_
58-9	8666-8673	treated	_
58-10	8674-8676	as	_
58-11	8677-8680	the	_
58-12	8681-8689	baseline	_
58-13	8690-8698	time‐bin	_
58-14	8699-8701	T0	_
58-15	8702-8703	,	_
58-16	8704-8708	with	_
58-17	8709-8713	each	_
58-18	8714-8724	subsequent	_
58-19	8725-8733	time‐bin	_
58-20	8734-8735	(	_
58-21	8736-8741	T1–15	_
58-22	8742-8743	)	_
58-23	8744-8752	compared	_
58-24	8753-8757	with	_
58-25	8758-8760	T0	_
58-26	8761-8766	using	_
58-27	8767-8777	regression	_
58-28	8778-8786	analysis	_
58-29	8787-8793	within	_
58-30	8794-8795	a	_
58-31	8796-8803	general	_
58-32	8804-8810	linear	_
58-33	8811-8816	model	_
58-34	8817-8826	framework	_
58-35	8827-8828	.	_

Text=The exact shape of the signal of interest was unknown; therefore, no high‐pass filter was used.
59-1	8829-8832	The	_
59-2	8833-8838	exact	_
59-3	8839-8844	shape	_
59-4	8845-8847	of	_
59-5	8848-8851	the	_
59-6	8852-8858	signal	_
59-7	8859-8861	of	_
59-8	8862-8870	interest	_
59-9	8871-8874	was	_
59-10	8875-8882	unknown	_
59-11	8883-8884	;	_
59-12	8885-8894	therefore	_
59-13	8895-8896	,	_
59-14	8897-8899	no	_
59-15	8900-8909	high‐pass	_
59-16	8910-8916	filter	_
59-17	8917-8920	was	_
59-18	8921-8925	used	_
59-19	8926-8927	.	_

Text=The neutral session averages were subtracted from the time equivalent drug cue session averages, resulting in ‘ drug cue session–neutral session ’ contrast images.
60-1	8928-8931	The	_
60-2	8932-8939	neutral	_
60-3	8940-8947	session	_
60-4	8948-8956	averages	_
60-5	8957-8961	were	_
60-6	8962-8972	subtracted	_
60-7	8973-8977	from	_
60-8	8978-8981	the	_
60-9	8982-8986	time	_
60-10	8987-8997	equivalent	_
60-11	8998-9002	drug	_
60-12	9003-9006	cue	_
60-13	9007-9014	session	_
60-14	9015-9023	averages	_
60-15	9024-9025	,	_
60-16	9026-9035	resulting	_
60-17	9036-9038	in	_
60-18	9039-9040	‘	_
60-19	9041-9045	drug	_
60-20	9046-9049	cue	_
60-21	9050-9065	session–neutral	_
60-22	9066-9073	session	_
60-23	9074-9075	’	_
60-24	9076-9084	contrast	_
60-25	9085-9091	images	_
60-26	9092-9093	.	_

Text=Region‐of‐interest analysis A region‐of‐interest (ROI) approach was used to extract time course signals from key brain regions involved in drug cue reactivity based on recent meta‐analyses (Chase et al.
61-1	9094-9112	Region‐of‐interest	_
61-2	9113-9121	analysis	_
61-3	9122-9123	A	_
61-4	9124-9142	region‐of‐interest	_
61-5	9143-9144	(	_
61-6	9145-9148	ROI	_
61-7	9149-9150	)	_
61-8	9151-9159	approach	_
61-9	9160-9163	was	_
61-10	9164-9168	used	_
61-11	9169-9171	to	_
61-12	9172-9179	extract	_
61-13	9180-9184	time	_
61-14	9185-9191	course	_
61-15	9192-9199	signals	_
61-16	9200-9204	from	_
61-17	9205-9208	key	_
61-18	9209-9214	brain	_
61-19	9215-9222	regions	_
61-20	9223-9231	involved	_
61-21	9232-9234	in	_
61-22	9235-9239	drug	_
61-23	9240-9243	cue	_
61-24	9244-9254	reactivity	_
61-25	9255-9260	based	_
61-26	9261-9263	on	_
61-27	9264-9270	recent	_
61-28	9271-9284	meta‐analyses	_
61-29	9285-9286	(	_
61-30	9287-9292	Chase	_
61-31	9293-9295	et	_
61-32	9296-9298	al	_
61-33	9299-9300	.	_

Text=2011; Kuhn & Gallinat 2011).
62-1	9301-9305	2011	_
62-2	9306-9307	;	_
62-3	9308-9312	Kuhn	_
62-4	9313-9314	&	_
62-5	9315-9323	Gallinat	_
62-6	9324-9328	2011	_
62-7	9329-9330	)	_
62-8	9331-9332	.	_

Text=These composed of spheres of 7‐mm radius centred around the bilateral ventral striatum, amygdala and VmPFC, coordinates from Chase et al.
63-1	9333-9338	These	_
63-2	9339-9347	composed	_
63-3	9348-9350	of	_
63-4	9351-9358	spheres	_
63-5	9359-9361	of	_
63-6	9362-9366	7‐mm	_
63-7	9367-9373	radius	_
63-8	9374-9381	centred	_
63-9	9382-9388	around	_
63-10	9389-9392	the	_
63-11	9393-9402	bilateral	_
63-12	9403-9410	ventral	_
63-13	9411-9419	striatum	_
63-14	9420-9421	,	_
63-15	9422-9430	amygdala	_
63-16	9431-9434	and	_
63-17	9435-9440	VmPFC	_
63-18	9441-9442	,	_
63-19	9443-9454	coordinates	_
63-20	9455-9459	from	_
63-21	9460-9465	Chase	_
63-22	9466-9468	et	_
63-23	9469-9471	al	_
63-24	9472-9473	.	_

Text=(2011), and anterior cingulate cortex, coordinates from Kuhn & Gallinat (2011), as displayed in Fig.
64-1	9474-9475	(	_
64-2	9476-9480	2011	_
64-3	9481-9482	)	_
64-4	9483-9484	,	_
64-5	9485-9488	and	_
64-6	9489-9497	anterior	_
64-7	9498-9507	cingulate	_
64-8	9508-9514	cortex	_
64-9	9515-9516	,	_
64-10	9517-9528	coordinates	_
64-11	9529-9533	from	_
64-12	9534-9538	Kuhn	_
64-13	9539-9540	&	_
64-14	9541-9549	Gallinat	_
64-15	9550-9551	(	_
64-16	9552-9556	2011	_
64-17	9557-9558	)	_
64-18	9559-9560	,	_
64-19	9561-9563	as	_
64-20	9564-9573	displayed	_
64-21	9574-9576	in	_
64-22	9577-9580	Fig	_
64-23	9581-9582	.	_

Text=3.
65-1	9583-9584	3	_
65-2	9585-9586	.	_

Text=Mean drug cue‐neutral session contrast estimates were extracted from each of the six ROIs using the Easy ROI toolbox implemented in SPM (http: //www.sbirc.ed.ac.uk/LCL/LCL_M1.html) and entered into mixed ANOVAs in SPSS (version 20) to investigate effects of time and group on drug cue‐neutral session BOLD signal.
66-1	9587-9591	Mean	_
66-2	9592-9596	drug	_
66-3	9597-9608	cue‐neutral	_
66-4	9609-9616	session	_
66-5	9617-9625	contrast	_
66-6	9626-9635	estimates	_
66-7	9636-9640	were	_
66-8	9641-9650	extracted	_
66-9	9651-9655	from	_
66-10	9656-9660	each	_
66-11	9661-9663	of	_
66-12	9664-9667	the	_
66-13	9668-9671	six	_
66-14	9672-9676	ROIs	_
66-15	9677-9682	using	_
66-16	9683-9686	the	_
66-17	9687-9691	Easy	_
66-18	9692-9695	ROI	_
66-19	9696-9703	toolbox	_
66-20	9704-9715	implemented	_
66-21	9716-9718	in	_
66-22	9719-9722	SPM	_
66-23	9723-9724	(	_
66-24	9725-9729	http	_
66-25	9730-9731	:	_
66-26	9732-9768	//www.sbirc.ed.ac.uk/LCL/LCL_M1.html	_
66-27	9769-9770	)	_
66-28	9771-9774	and	_
66-29	9775-9782	entered	_
66-30	9783-9787	into	_
66-31	9788-9793	mixed	_
66-32	9794-9800	ANOVAs	_
66-33	9801-9803	in	_
66-34	9804-9808	SPSS	_
66-35	9809-9810	(	_
66-36	9811-9818	version	_
66-37	9819-9821	20	_
66-38	9822-9823	)	_
66-39	9824-9826	to	_
66-40	9827-9838	investigate	_
66-41	9839-9846	effects	_
66-42	9847-9849	of	_
66-43	9850-9854	time	_
66-44	9855-9858	and	_
66-45	9859-9864	group	_
66-46	9865-9867	on	_
66-47	9868-9872	drug	_
66-48	9873-9884	cue‐neutral	_
66-49	9885-9892	session	_
66-50	9893-9897	BOLD	_
66-51	9898-9904	signal	_
66-52	9905-9906	.	_

Text=Investigations were carried out for the whole session (T0 to T15) and for the video time‐bins (T1–T10) and post‐video time‐bins separately (T11 to T15) with session order included as a covariate.
67-1	9907-9921	Investigations	_
67-2	9922-9926	were	_
67-3	9927-9934	carried	_
67-4	9935-9938	out	_
67-5	9939-9942	for	_
67-6	9943-9946	the	_
67-7	9947-9952	whole	_
67-8	9953-9960	session	_
67-9	9961-9962	(	_
67-10	9963-9965	T0	_
67-11	9966-9968	to	_
67-12	9969-9972	T15	_
67-13	9973-9974	)	_
67-14	9975-9978	and	_
67-15	9979-9982	for	_
67-16	9983-9986	the	_
67-17	9987-9992	video	_
67-18	9993-10002	time‐bins	_
67-19	10003-10004	(	_
67-20	10005-10011	T1–T10	_
67-21	10012-10013	)	_
67-22	10014-10017	and	_
67-23	10018-10028	post‐video	_
67-24	10029-10038	time‐bins	_
67-25	10039-10049	separately	_
67-26	10050-10051	(	_
67-27	10052-10055	T11	_
67-28	10056-10058	to	_
67-29	10059-10062	T15	_
67-30	10063-10064	)	_
67-31	10065-10069	with	_
67-32	10070-10077	session	_
67-33	10078-10083	order	_
67-34	10084-10092	included	_
67-35	10093-10095	as	_
67-36	10096-10097	a	_
67-37	10098-10107	covariate	_
67-38	10108-10109	.	_

Text=A Greenhouse‐Geisser correction was applied when Mauchley's assumption of sphericity was violated.
68-1	10110-10111	A	_
68-2	10112-10130	Greenhouse‐Geisser	_
68-3	10131-10141	correction	_
68-4	10142-10145	was	_
68-5	10146-10153	applied	_
68-6	10154-10158	when	_
68-7	10159-10167	Mauchley	_
68-8	10168-10170	's	_
68-9	10171-10181	assumption	_
68-10	10182-10184	of	_
68-11	10185-10195	sphericity	_
68-12	10196-10199	was	_
68-13	10200-10208	violated	_
68-14	10209-10210	.	_

Text=A Bonferroni correction for the six separate ROIs results in a significance value of p <0.008 for this analysis.
69-1	10211-10212	A	_
69-2	10213-10223	Bonferroni	_
69-3	10224-10234	correction	_
69-4	10235-10238	for	_
69-5	10239-10242	the	_
69-6	10243-10246	six	_
69-7	10247-10255	separate	_
69-8	10256-10260	ROIs	_
69-9	10261-10268	results	_
69-10	10269-10271	in	_
69-11	10272-10273	a	_
69-12	10274-10286	significance	_
69-13	10287-10292	value	_
69-14	10293-10295	of	_
69-15	10296-10297	p	_
69-16	10298-10299	<	_
69-17	10300-10305	0.008	_
69-18	10306-10309	for	_
69-19	10310-10314	this	_
69-20	10315-10323	analysis	_
69-21	10324-10325	.	_

Text=However, this is a conservative approach, which may result in false negatives.
70-1	10326-10333	However	_
70-2	10334-10335	,	_
70-3	10336-10340	this	_
70-4	10341-10343	is	_
70-5	10344-10345	a	_
70-6	10346-10358	conservative	_
70-7	10359-10367	approach	_
70-8	10368-10369	,	_
70-9	10370-10375	which	_
70-10	10376-10379	may	_
70-11	10380-10386	result	_
70-12	10387-10389	in	_
70-13	10390-10395	false	_
70-14	10396-10405	negatives	_
70-15	10406-10407	.	_

Text=Results are therefore reported significant at p <0.05 with results surviving Bonferroni correction highlighted.
71-1	10408-10415	Results	_
71-2	10416-10419	are	_
71-3	10420-10429	therefore	_
71-4	10430-10438	reported	_
71-5	10439-10450	significant	_
71-6	10451-10453	at	_
71-7	10454-10455	p	_
71-8	10456-10457	<	_
71-9	10458-10462	0.05	_
71-10	10463-10467	with	_
71-11	10468-10475	results	_
71-12	10476-10485	surviving	_
71-13	10486-10496	Bonferroni	_
71-14	10497-10507	correction	_
71-15	10508-10519	highlighted	_
71-16	10520-10521	.	_

Text=ROI BOLD signal time course and subjective rating time course temporal correlation analysis In participants reporting a subjective rating change in response to the drug cue session, we investigated whether their subjective rating time course was temporally correlated with fMRI signal in the ROIs.
72-1	10522-10525	ROI	_
72-2	10526-10530	BOLD	_
72-3	10531-10537	signal	_
72-4	10538-10542	time	_
72-5	10543-10549	course	_
72-6	10550-10553	and	_
72-7	10554-10564	subjective	_
72-8	10565-10571	rating	_
72-9	10572-10576	time	_
72-10	10577-10583	course	_
72-11	10584-10592	temporal	_
72-12	10593-10604	correlation	_
72-13	10605-10613	analysis	_
72-14	10614-10616	In	_
72-15	10617-10629	participants	_
72-16	10630-10639	reporting	_
72-17	10640-10641	a	_
72-18	10642-10652	subjective	_
72-19	10653-10659	rating	_
72-20	10660-10666	change	_
72-21	10667-10669	in	_
72-22	10670-10678	response	_
72-23	10679-10681	to	_
72-24	10682-10685	the	_
72-25	10686-10690	drug	_
72-26	10691-10694	cue	_
72-27	10695-10702	session	_
72-28	10703-10704	,	_
72-29	10705-10707	we	_
72-30	10708-10720	investigated	_
72-31	10721-10728	whether	_
72-32	10729-10734	their	_
72-33	10735-10745	subjective	_
72-34	10746-10752	rating	_
72-35	10753-10757	time	_
72-36	10758-10764	course	_
72-37	10765-10768	was	_
72-38	10769-10779	temporally	_
72-39	10780-10790	correlated	_
72-40	10791-10795	with	_
72-41	10796-10800	fMRI	_
72-42	10801-10807	signal	_
72-43	10808-10810	in	_
72-44	10811-10814	the	_
72-45	10815-10819	ROIs	_
72-46	10820-10821	.	_

Text=Analyses were restricted to subjective ratings and ROI BOLD signal time courses, demonstrating significant effects in the ANOVAs.
73-1	10822-10830	Analyses	_
73-2	10831-10835	were	_
73-3	10836-10846	restricted	_
73-4	10847-10849	to	_
73-5	10850-10860	subjective	_
73-6	10861-10868	ratings	_
73-7	10869-10872	and	_
73-8	10873-10876	ROI	_
73-9	10877-10881	BOLD	_
73-10	10882-10888	signal	_
73-11	10889-10893	time	_
73-12	10894-10901	courses	_
73-13	10902-10903	,	_
73-14	10904-10917	demonstrating	_
73-15	10918-10929	significant	_
73-16	10930-10937	effects	_
73-17	10938-10940	in	_
73-18	10941-10944	the	_
73-19	10945-10951	ANOVAs	_
73-20	10952-10953	.	_

Text=Before correlations were carried out, the pre‐video baseline subjective rating was subtracted from each video and post‐video rating for each session.
74-1	10954-10960	Before	_
74-2	10961-10973	correlations	_
74-3	10974-10978	were	_
74-4	10979-10986	carried	_
74-5	10987-10990	out	_
74-6	10991-10992	,	_
74-7	10993-10996	the	_
74-8	10997-11006	pre‐video	_
74-9	11007-11015	baseline	_
74-10	11016-11026	subjective	_
74-11	11027-11033	rating	_
74-12	11034-11037	was	_
74-13	11038-11048	subtracted	_
74-14	11049-11053	from	_
74-15	11054-11058	each	_
74-16	11059-11064	video	_
74-17	11065-11068	and	_
74-18	11069-11079	post‐video	_
74-19	11080-11086	rating	_
74-20	11087-11090	for	_
74-21	11091-11095	each	_
74-22	11096-11103	session	_
74-23	11104-11105	.	_

Text=The neutral session ratings were then subtracted from the drug cue session ratings.
75-1	11106-11109	The	_
75-2	11110-11117	neutral	_
75-3	11118-11125	session	_
75-4	11126-11133	ratings	_
75-5	11134-11138	were	_
75-6	11139-11143	then	_
75-7	11144-11154	subtracted	_
75-8	11155-11159	from	_
75-9	11160-11163	the	_
75-10	11164-11168	drug	_
75-11	11169-11172	cue	_
75-12	11173-11180	session	_
75-13	11181-11188	ratings	_
75-14	11189-11190	.	_

Text=This was to ensure both the fMRI and subjective rating data reflected drug cue session changes from baseline minus neutral session changes from baseline (fMRI data already in this format after first‐level analysis).
76-1	11191-11195	This	_
76-2	11196-11199	was	_
76-3	11200-11202	to	_
76-4	11203-11209	ensure	_
76-5	11210-11214	both	_
76-6	11215-11218	the	_
76-7	11219-11223	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
76-8	11224-11227	and	_
76-9	11228-11238	subjective	_
76-10	11239-11245	rating	_
76-11	11246-11250	data	_
76-12	11251-11260	reflected	_
76-13	11261-11265	drug	_
76-14	11266-11269	cue	_
76-15	11270-11277	session	_
76-16	11278-11285	changes	_
76-17	11286-11290	from	_
76-18	11291-11299	baseline	_
76-19	11300-11305	minus	_
76-20	11306-11313	neutral	_
76-21	11314-11321	session	_
76-22	11322-11329	changes	_
76-23	11330-11334	from	_
76-24	11335-11343	baseline	_
76-25	11344-11345	(	_
76-26	11346-11350	fMRI	_
76-27	11351-11355	data	_
76-28	11356-11363	already	_
76-29	11364-11366	in	_
76-30	11367-11371	this	_
76-31	11372-11378	format	_
76-32	11379-11384	after	_
76-33	11385-11396	first‐level	_
76-34	11397-11405	analysis	_
76-35	11406-11407	)	_
76-36	11408-11409	.	_

Text=Finally, the fMRI BOLD signal data were averaged over 3‐minute intervals to reflect the 3‐minute interval of subjective rating presentation during each session.
77-1	11410-11417	Finally	_
77-2	11418-11419	,	_
77-3	11420-11423	the	_
77-4	11424-11428	fMRI	_
77-5	11429-11433	BOLD	_
77-6	11434-11440	signal	_
77-7	11441-11445	data	_
77-8	11446-11450	were	_
77-9	11451-11459	averaged	_
77-10	11460-11464	over	_
77-11	11465-11473	3‐minute	_
77-12	11474-11483	intervals	_
77-13	11484-11486	to	_
77-14	11487-11494	reflect	_
77-15	11495-11498	the	_
77-16	11499-11507	3‐minute	_
77-17	11508-11516	interval	_
77-18	11517-11519	of	_
77-19	11520-11530	subjective	_
77-20	11531-11537	rating	_
77-21	11538-11550	presentation	_
77-22	11551-11557	during	_
77-23	11558-11562	each	_
77-24	11563-11570	session	_
77-25	11571-11572	.	_

Text=Correlational analyses were carried out between each individual's subjective rating and ROI BOLD signal time courses using Pearson's product moment correlation coefficient.
78-1	11573-11586	Correlational	_
78-2	11587-11595	analyses	_
78-3	11596-11600	were	_
78-4	11601-11608	carried	_
78-5	11609-11612	out	_
78-6	11613-11620	between	_
78-7	11621-11625	each	_
78-8	11626-11636	individual	_
78-9	11637-11639	's	_
78-10	11640-11650	subjective	_
78-11	11651-11657	rating	_
78-12	11658-11661	and	_
78-13	11662-11665	ROI	_
78-14	11666-11670	BOLD	_
78-15	11671-11677	signal	_
78-16	11678-11682	time	_
78-17	11683-11690	courses	_
78-18	11691-11696	using	_
78-19	11697-11704	Pearson	_
78-20	11705-11707	's	_
78-21	11708-11715	product	_
78-22	11716-11722	moment	_
78-23	11723-11734	correlation	_
78-24	11735-11746	coefficient	_
78-25	11747-11748	.	_

Text=Resultant correlation coefficients were Fisher's z‐transformed and entered into one‐sample t‐tests to determine group level significance.
79-1	11749-11758	Resultant	_
79-2	11759-11770	correlation	_
79-3	11771-11783	coefficients	_
79-4	11784-11788	were	_
79-5	11789-11795	Fisher	_
79-6	11796-11798	's	_
79-7	11799-11812	z‐transformed	_
79-8	11813-11816	and	_
79-9	11817-11824	entered	_
79-10	11825-11829	into	_
79-11	11830-11840	one‐sample	_
79-12	11841-11848	t‐tests	_
79-13	11849-11851	to	_
79-14	11852-11861	determine	_
79-15	11862-11867	group	_
79-16	11868-11873	level	_
79-17	11874-11886	significance	_
79-18	11887-11888	.	_

